233 related articles for article (PubMed ID: 29537654)
21. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
[TBL] [Abstract][Full Text] [Related]
22. Multipurpose prevention technologies: products in development.
Friend DR; Clark JT; Kiser PF; Clark MR
Antiviral Res; 2013 Dec; 100 Suppl():S39-47. PubMed ID: 24188708
[TBL] [Abstract][Full Text] [Related]
23. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.
Mack N; Evens EM; Tolley EE; Brelsford K; Mackenzie C; Milford C; Smit JA; Kimani J
J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616
[TBL] [Abstract][Full Text] [Related]
24. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
25. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
[TBL] [Abstract][Full Text] [Related]
26. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.
Walensky RP; Jacobsen MM; Bekker LG; Parker RA; Wood R; Resch SC; Horstman NK; Freedberg KA; Paltiel AD
J Infect Dis; 2016 May; 213(10):1523-31. PubMed ID: 26681778
[TBL] [Abstract][Full Text] [Related]
27. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
[TBL] [Abstract][Full Text] [Related]
28. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
[TBL] [Abstract][Full Text] [Related]
29. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel.
Ginsberg GM; Chemtob D
BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
[TBL] [Abstract][Full Text] [Related]
31. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
[TBL] [Abstract][Full Text] [Related]
32. Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.
Jewell BL; Cremin I; Pickles M; Celum C; Baeten JM; Delany-Moretlwe S; Hallett TB
PLoS One; 2015; 10(1):e0115511. PubMed ID: 25616135
[TBL] [Abstract][Full Text] [Related]
33. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
[TBL] [Abstract][Full Text] [Related]
35. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.
Terris-Prestholt F; Hanson K; MacPhail C; Vickerman P; Rees H; Watts C
PLoS One; 2013; 8(12):e83193. PubMed ID: 24386160
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
[TBL] [Abstract][Full Text] [Related]
37. HIV pre-exposure prophylaxis for female sex workers: ensuring women's family planning needs are not left behind.
Bowring AL; Ampt FH; Schwartz S; Stoové MA; Luchters S; Baral S; Hellard M
J Int AIDS Soc; 2020 Feb; 23(2):e25442. PubMed ID: 32064765
[TBL] [Abstract][Full Text] [Related]
38. Lessons from reproductive health to inform multipurpose prevention technologies: don't reinvent the wheel.
Brady M; Manning J
Antiviral Res; 2013 Dec; 100 Suppl():S25-31. PubMed ID: 24188700
[TBL] [Abstract][Full Text] [Related]
39. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.
Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040
[TBL] [Abstract][Full Text] [Related]
40. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Shahmanesh M; Hargreaves JR; Smith J; Revill P; Sibanda E; Ehrenkranz P; Sikwese K; Rodger A; Lundgren JD; Gilks CF; Godfrey C; Cowan F; Cambiano V
Lancet Glob Health; 2023 Oct; 11(10):e1648-e1657. PubMed ID: 37734807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]